ANZCTR search results

.This study is evaluating the safety and efficacy of Dendritic cell Immune activation combined with Venetoclax and Azacitidine as frontline therapy for patients with newly diagnosed acute myeloid leukaemia unfit for intensive chemotherapy Who is it for? You may be eligible to join this study if you are aged 18 years or above, have been diagnosed with acute myeloid leukaemia unfit for intensive chemotherapy and receiving Venetoclax-Azacitidine as frontline induction therapy Study details All participants will receive Vididencel (an off-the-shelf allogeneic dendritic cell immune activator) in combination with standard-of-care Venetoclax and Azacitidine. Vididencel treatment regimen consists of four priming doses administered on Day 1 and 15 of Cycles 1 and 2 followed by two booster doses administered on Day 1 of Cycles 4 and 5. Participants will be assessed for safety and tolerability using clinical examination, blood tests, vital sign monitoring, reporting of adverse events for the duration of their treatment over the first 6 months. Measurable Residual Disease will be assessed using examination of blood cells and molecular markers during each cycle until the end of the study over 3 years

The purpose of the A2P biobank is to collect repeated clinical measures, MRI imaging and biological samples from patients with progressive supranuclear palsy, multiple system atrophy, corticobasal syndrome as well as Parkinson’s disease. Allowing future researchers to potentially find new tests for earlier and more accurate diagnosis, accurate predictors of disease progression and effective new treatments.

This first-in-human, double-blind, placebo-controlled phase 1a study in healthy participants designed to assess the safety and tolerability of MMB-003. This study consists of 2 parts: 1. Part 1 will assess single ascending doses (SAD) in 3 cohorts of healthy male and female participants. Each cohort will consist of 4 participants (3 active:1 placebo) across both parts of the study; thus, a total of 12 healthy volunteers and up to 16 UC participants are planned to be enrolled.

This first-in-human, double-blind, placebo-controlled phase 2a study in participants with UC designed to assess the safety and tolerability of MMB-003. This study consists of 2 parts. Part 2 will assess multiple ascending doses (MAD) in 3 cohorts of male and female participants with UC. An additional 4 participants may be enrolled in the study in any of the MAD cohorts once the safety data has been obtained and the dose level has been cleared.

This study will investigate whether providing immediate access to HIV Peer Navigation improves the experiences and quality of life of people newly diagnosed with HIV. Twenty-four adults newly diagnosed with HIV will be randomly allocated to receive either immediate HIV Peer Navigation or standard HIV care. Participants will complete monthly quality-of-life surveys for six months, and some participants, health professionals and peer navigators will take part in interviews about their experiences. The study will examine whether immediate peer support improves quality of life and engagement with care following diagnosis. The findings will help determine whether immediate HIV Peer Navigation is a feasible and effective model of support for people newly diagnosed with HIV.

This study is testing whether using HEPA filter air purifiers at home can improve health outcomes for adults with moderate to severe chronic obstructive pulmonary disease (COPD),. Adults with COPD will be randomly assigned to receive either a real HEPA air purifier or a look-alike placebo purifier that does not filter the air. The study will assess whether the intervention reduces COPD-related hospitalisations and exacerbations, while also evaluating changes in respiratory symptoms, quality of life, sleep quality, lung function, and healthcare utilisation before and after the intervention.

Glaucoma is a progressive and blinding eye condition. A key challenge is identifying people most at risk of rapid progression. Good blood supply is important in glaucoma. Poor blood flow to the retina may contribute to nerve cell injury and can happen before permanent tissue damage. Flickering light is a well-established stress test that can be used to induce dilation of blood vessels in the eye. This study adds to our fundamental understanding of how retinal vessels respond to stress induced by flickering light. We will take scans of the retina and its blood vessels using a commonly available imaging technique called optical coherence tomography angiography (OCTA) to image blood vessels in the eye non-invasively. Using OCTA and a custom-designed device that attaches to the camera lens to deliver a flickering light stimulus, we will study the effect of flicker on the different layers of blood vessels in the retina, adding to our understanding of how blood flow is redistributed in times of increased retinal activity. This technique is called flicker tomography angiography (FTA). We will give participants nicotinamide (NAM, a form of vitamin B3) to determine whether FTA can detect the changes in retinal blood flow induced by NAM.

Is it feasible to conduct a double blind, randomised clinical trial to administer a nutritional supplement - exogenous enteral ketone ester - in critically ill, mechanically ventilated patients? We aim to find the correct dose required to maintain a participants blood ketone level between 2 and 5 mmol/L. We will also monitor for any side effects of the intervention

This study aims to assess acute safety and efficacy of a novel non-invasive neurostimulation approach in the treatment of obstructive sleep apnoea. In this study, we will assess the acute effect of transmucosal palatal stimulation on apnoea-hypopnoea index and ascertain initial safety and tolerability outcome data.

Extreme weather events attributable to climate change are occurring with increasing frequency and intensity. Whilst extreme temperatures can affect people of all ages and health status, certain populations are more vulnerable, especially older adults and those who have pre-existing chronic conditions such as cardiovascular diseases. Vulnerable populations are more sensitive to heat-related health risks and are more likely to suffer morbidity and mortality associated with heatwave exposure. As population exposure to extreme heat rises and our population ages, the associated health burden will continue to grow. The trial purpose is to evaluate whether a tailored text messaging intervention can reduce patient-reported heat symptoms, increase adoption of heat adaptive behaviours and reduce utilisation of health services during and after extreme heat days for Australian adults living with chronic conditions.